Production of poliovirus at high titers for vaccine production
US9022240B2 · kind B2 · utility
1Cited by
13References
33Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 12, 2014 |
| Grant date | May 5, 2015 |
| Priority date | — |
| Expiry date | May 12, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.